$148.85
3.59%
NYSE, Nov 16, 04:00 pm EST. Closed.

PerkinElmer Stock price

$148.85
-3.79 2.48% 1M
+53.37 55.90% 6M
+52.10 53.85% YTD
+57.79 63.46% 1Y
+60.65 68.76% 3Y
-38.66 20.62% 5Y
+97.39 189.25% 10Y
+127.45 595.56% 20Y
NYSE, Closing price Mon, Nov 16 2026
-5.54 3.59%

AI Insights on PerkinElmer Insights AI Insights on PerkinElmer

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is PerkinElmer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$16.6b
Enterprise Value
$18.7b
Net debt
$2.0b
Cash
$592.8m
Shares outstanding
111.6m
Valuation
P/E
66.2
P/S | estimate
5.6 | 5.7
EV/Sales | estimate
6.3 | 6.4
EV/FCF | ex SBC
31.6 | -
P/B
2.3
Dividends
DPS
$0.28
Yield 1Y | 5Y
0.2% | 0.2%
Growth 1Y | 5Y
0.0% | 0.0%
Payout 1Y | 3Y
13.6% | 8.6%
Increased
0 Years
Financials
Revenue | estimate
$2.9b | $2.9b
EBITDA
$785.2m
EBIT
$372.1m
Net Income
$253.2m
Free Cash Flow | ex SBC
$590.5m | -
Growth
Revenue | estimate
4.6% | 2.7%
EBITDA
-3.2%
EBIT
-7.8%
Net Income
6.6%
Free Cash Flow
18.7%
Margin
Gross
55.9%
EBITDA
26.7%
EBIT
12.7%
Net
8.6%
Free Cash Flow | ex SBC
20.1% | -
Financial Health
Equity Ratio
59.6%
Return on Equity
3.3%
ROCE
3.5%
ROIC
3.1%
Debt/Equity
0.4
More
EPS
$2.3
FCF per Share
$5.3
Short interest
8.8%
Employees
11k
Rev per Employee
$260.0k

PerkinElmer Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a PerkinElmer forecast:

11x Buy
44%
14x Hold
56%

Analyst Opinions

25 Analysts have issued a PerkinElmer forecast:

Buy
44%
Hold
56%

PerkinElmer Events

Past Events
NOV
3
Q3 2026 Earnings Call
14 days ago
SEP
15
2026 Global Healthcare Conference
2 months ago
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
SEP
9
Wells Fargo 21st Annual Healthcare Conference
2 months ago
AUG
4
Q2 2026 Earnings Call
4 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
13
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
5
Q1 2026 Earnings Call
7 months ago
MAR
10
Barclays 28th Annual Global Healthcare Conference
8 months ago
MAR
3
TD Cowen 46th Annual Health Care Conference
9 months ago
MAR
2
47th Annual Raymond James Institutional Investor Conference
9 months ago
FEB
2
Q4 2025 Earnings Call
10 months ago
JAN
13
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
2
Citi Annual Global Healthcare Conference 2025
12 months ago
NOV
18
Jefferies London Healthcare Conference 2025
12 months ago
NOV
10
UBS Global Healthcare Conference 2025
about one year ago
OCT
27
Q3 2025 Earnings Call
about one year ago

Financial data from PerkinElmer

Oct '26
+/-
%
2,942 2,942
5% 5%
100%
- Direct Costs 1,297 1,297
3% 3%
44%
1,645 1,645
6% 6%
56%
- Selling and Administrative Expenses 809 809
15% 15%
27%
- Research and Development Expense 213 213
3% 3%
7%
785 785
3% 3%
27%
- Depreciation and Amortization 413 413
1% 1%
14%
EBIT (Operating Income) EBIT 372 372
8% 8%
13%
Net Profit 253 253
7% 7%
9%

In millions USD.

Don't miss a Thing! We will send you all news about PerkinElmer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PerkinElmer Stock News

Neutral
Business Wire
●
4 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today will host its 2026 Investor Day, highlighting the Company's differentiated portfolio of Life Sciences and Diagnostics solutions, as well as its position at the intersection of biology, experimentation and data. Under the theme "Powering Scientific Intelligence," Prahlad Singh, president and chief executive officer, and members of...
Positive
Investors Business Daily
●
14 days ago
Medical research stock Revvity surged on the back of a strong third-quarter report and heightened 2026 view.
More PerkinElmer News

Company Profile

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Head office United States
CEO Dr. Singh
Employees 11,000
Founded 1937
Website www.revvity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today